<p>They’re being hailed as an effective way to lose weight, but diabetes drugs like Ozempic may come with a heightened risk of severe gastrointestinal problems. New research from the University of British Columbia shows that medications known as GLP-1 agonists—which includes brands like Wegovy, Ozempic, Rybelsus and Saxenda—are associated with an increased risk of serious medical conditions including stomach paralysis, pancreatitis and bowel obstruction. It is the first large, population-level study to examine adverse gastrointestinal events in non-diabetic patients using the drugs specifically for weight loss. GLP-1 agonists were associated with a 9.09x higher risk of pacreatitis, 4.22x higher risk of bowel obstruction and 3.67x higher risk of gastroparesis.</p>
New Study Links Ozempic and Wegovy to Serious Gastrointestinal Conditions, Stomach Paralysis theepochtimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theepochtimes.com Daily Mail and Mail on Sunday newspapers.